Content
All Posts > Content under Pharma/Biotech
Visualizing The Future Of The Pharma Market
Article By:
Jeff Desjardins
Read
Wednesday, January 30, 2019 3:05 PM EDT
To meet the needs of this aging population, we will continue to need larger quantities and more varieties of prescription drug treatments – an industry that is expected to skyrocket to $1.2 trillion in size by 2024.
New Hope For Acorda Therapeutics In 2019
Article By:
Nascent Trader
Read
Monday, January 28, 2019 4:00 PM EDT
I recommend long Acorda Therapeutics (ACOR) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion.
Week In Review: China Green Lights Nasdaq-Style Exchange For Young Companies
Article By:
ChinaBio® Today
Read
Saturday, January 26, 2019 4:11 PM EDT
China has given the green light to a new registration-based Shanghai stock exchange aimed at high tech companies that will be less regulated than other China exchanges. The new exchange resembles Nasdaq with its dealer-to-dealer pricing mechanism.
Sun Pharma Surges By 5%; BSE Healthcare Index Up 0.9%
Article By:
Equitymaster India
Read
Tuesday, January 22, 2019 2:19 AM EDT
Among the top Gainers in the BSE Healthcare Index today are Sun Pharma (up 5.3%) and Sun Pharma Adv. Res. Abbott India and Wockhardt LTD. are among the top losers.
Johns Hopkins, Bristol-Myers Face $1 Billion Suit
Article By:
Tyler Durden
Read
Sunday, January 20, 2019 1:05 PM EDT
Johns Hopkins University, Bristol-Myers Squibb and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a top-secret program in the 1940s ran by the US government that injected hundreds of Guatemalans with syphilis.
In this article: BMY
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
Article By:
ChinaBio® Today
Read
Sunday, January 20, 2019 10:38 AM EDT
MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
Tilray May Soon Be Smokin’ Hot
Article By:
Bob Lang
Read
Wednesday, January 16, 2019 10:35 AM EDT
Marijuana stocks have been all the rage for about a year now, and Tilray has been one of the big horses. The medical marijuana name had an epic run higher last fall, moving from around $40 in September to a high of $300 on stellar turnover.
In this article: TLRY
Cannabis Stocks Back In An Uptrend
Article By:
Justin Smyth
Read
Tuesday, January 15, 2019 5:55 AM EDT
Cannabis stocks went on a big run after that announcement. But they topped out in October along with the stock market and many stocks in the sector went into a decline that broke below the 30-week moving average.
In this article: CGC
Hedgie Warns "Big Shake-Out Looms" After Banking $480 Million On Biotech Buyout
Article By:
Tyler Durden
Read
Sunday, January 13, 2019 4:06 PM EDT
Steve Elms of Aisling Capital made a huge score on one of the biggest deals of his career: Eli Lilly's purchase of Loxo Oncology, Inc. and he is forecasting a "big shake out on the horizon" for these types of companies in 2019.
